# WU-KONG6 (NCT05712902)

> Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05712902
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Dizal Pharmaceuticals
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Sunvozertinib
- Enrollment: 104
- Primary outcome: Objective Response Rate (ORR) according to RECIST 1.1 by an Independent Review Committee (IRC)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 10
- Podcasts: 5
- YouTube: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=wu-kong6-nct05712902

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05712902", "email": "<work email>"}; the inbox owner confirms by the emailed link.